Related Experiment Videos
Atrial fibrillation and anticoagulation
L F Garnier1, Ph Rouesnel, F Espitalier
1Service de cardiologie, Centre hospitalier, Vendôme.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|July 13, 2005
Summary
Atrial fibrillation (AF) stroke risk is reduced by anticoagulants like warfarin, but bleeding is a concern. New drugs like ximelagatran offer similar efficacy with fewer bleeds, improving stroke prevention.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly elevates ischemic stroke risk via left atrial thrombus formation.
- Anticoagulant therapy, primarily warfarin, reduces embolic events but increases bleeding, especially in the elderly, leading to underuse.
- Aspirin's efficacy in lone AF is less certain, potentially suitable for younger patients with low embolic risk.
Purpose of the Study:
- To review current anticoagulant strategies for stroke prevention in atrial fibrillation.
- To compare the efficacy and safety of various anticoagulant options.
- To emphasize individualized treatment decisions based on benefit-risk assessment.
Main Methods:
- Review of existing literature on anticoagulant therapies for atrial fibrillation.
- Comparison of warfarin, aspirin, and newer agents like ximelagatran.
- Consideration of urgent cardioversion protocols.
Main Results:
- Warfarin effectively reduces stroke risk but carries a bleeding risk.
- Low-dose aspirin may be an option for select patients, but combination with warfarin is contraindicated.
- Ximelagatran shows promise as an effective alternative to warfarin with a better bleeding profile.
- Intravenous unfractionated heparin is standard for urgent cardioversion; LMWH with TEE is an alternative approach.
Conclusions:
- Treatment decisions for AF patients must be individualized based on a careful benefit-risk ratio.
- Emerging anticoagulants like ximelagatran may offer improved safety profiles.
- Optimizing anticoagulant use in AF remains crucial for stroke prevention.